Abionyx Pharma SA
PAR:ABNX

Watchlist Manager
Abionyx Pharma SA Logo
Abionyx Pharma SA
PAR:ABNX
Watchlist
Price: 3.535 EUR 4.74% Market Closed
Market Cap: 123.5m EUR

Net Margin
Abionyx Pharma SA

-106.3%
Current
-98%
Average
-6.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-106.3%
=
Net Income
-4.6m
/
Revenue
4.3m

Net Margin Across Competitors

No Stocks Found

Abionyx Pharma SA
Glance View

Market Cap
123.7m EUR
Industry
Biotechnology

ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.

ABNX Intrinsic Value
3.449 EUR
Overvaluation 2%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-106.3%
=
Net Income
-4.6m
/
Revenue
4.3m
What is the Net Margin of Abionyx Pharma SA?

Based on Abionyx Pharma SA's most recent financial statements, the company has Net Margin of -106.3%.

Back to Top